摘要
骨量受多种遗传及环境因素共同影响,其中遗传因素对骨密度的影响大于60%。近年的研究显示,低密度脂蛋白受体相关蛋白5(LRP5)与成骨细胞分化、骨密度和/或骨质疏松性骨折关系密切。LRP5参与的骨量调控机制为骨质疏松症等疾病提供了新的治疗靶点,针对以上机制研制特异性激动剂或拮抗剂对开发新型抗骨质疏松药物具有重要意义。
Bone mass is affected by multiple genetic and environmental factors,genetic factors contribute to more than 60% of the variance in bone mineral density（BMD）.Recently,researches suggested that low-density lipoprotein receptor-related protein 5（LRP5） was closely related to differentiation of osteoblasts,BMD and/or osteoporotic fracture.The regulation mechanisms of bone mass which LRP5 involved in provide new insights into treat osteoporosis,and specific agonists or antagonists in these pathways could be potential targets for new anti-osteoporosis drugs.
出处
《基础医学与临床》
CSCD
北大核心
2011年第9期1060-1063,共4页
Basic and Clinical Medicine
基金
国家自然科学基金科学部主任基金(30440074)
国家科技支撑计划项目(2008BAl58802)
关键词
低密度脂蛋白受体相关蛋白5
骨量
成骨细胞
low-density lipoprotein receptor-related protein 5（LRP5）
bone mass
osteoblast
